June 02, 2025 a 07:43 am

BSX: Fundamental Ratio Analysis - Boston Scientific Corporation

Boston Scientific Corporation Stock

Boston Scientific Corporation, a leader in medical device innovation, has shown steady growth prospects fueled by its expanding product portfolio in the healthcare sector. The stock's fundamental ratings and analyst projections provide a positive outlook for potential investors. However, market conditions and industry-specific risks should still be carefully considered.

Fundamental Rating

Boston Scientific Corporation has a solid fundamental rating overall, reflecting a balanced approach to value and growth strategies.

Category Score Visualization
Discounted Cash Flow (DCF) 4
Return on Equity (ROE) 4
Return on Assets (ROA) 4
Debt to Equity 2
Price to Earnings (P/E) 1
Price to Book (P/B) 1

Historical Rating

The following table displays the historical fundamental scores of Boston Scientific Corporation.

Date Overall Score DCF ROE ROA Debt to Equity P/E P/B
2025-05-30 3 4 4 4 2 1 1
Previous 0 4 4 4 2 1 1

Analyst Price Targets

Analyst price targets for Boston Scientific Corporation indicate a generally positive outlook, with a consensus leaning towards a buy recommendation.

High Low Median Consensus
$130 $100 $117 $117.2
Stock Chart BSX

Analyst Sentiment

The analyst sentiment for Boston Scientific Corporation reflects a strong buy inclination, supported by a majority of buy recommendations.

Recommendation Count Visualization
Strong Buy 2
Buy 36
Hold 3
Sell 0
Strong Sell 0

Conclusion

Boston Scientific Corporation presents a compelling investment opportunity, supported by solid fundamentals and strong analyst sentiment. The company's diversified product line and robust market position enhance its growth potential. However, investors should remain vigilant about industry dynamics and macroeconomic challenges. Careful analysis and strategic decision-making will be key to maximizing returns while managing potential risks.